Merck's Gardasil is the first vaccine to prevent women from cervical cancer.
Drug maker Merck & Co.'s Gardasil, the first vaccine to prevent women from cervical cancer, received a favorable opinion from a panel of European experts on Friday, a Reuters report said.
The London-based European Medicines Agency said its Committee for Medicinal Products for Human Use (CHMP) had recommended that the European Commission approve Gardasil for girls and women ages 9 to 26 for the prevention of cervical cancer, abnormal cells on the surface of the cervix and genital warts.
Recommendations for marketing approval by the committee are normally endorsed by the European Commission within a couple of months.
Gardasil is a new kind of vaccine that prevents cervical cancer by protecting against the sexually transmitted human papilloma virus (HPV) which can trigger tumours.
If licensed, Gardasil will be the first Human Papillomavirus vaccine in Europe. Gardasil won approval last month from the U.S. Food and Drug Administration and has been recommended by experts for use in U.S. girls as young as nine and young women up to age 26.
If approved, Merck plans to sell the vaccine in Europe through Sanofi Pasteur MSD, its joint venture with Sanofi Pasteur, Sanofi-Aventis SA's vaccine business.
( Source: Xinhuanet )